Want to see JP:4534 full AI Analyst Report?
Mochida Pharmaceutical Co., Ltd. (4534) Ratios
1 Followers
Mochida Pharmaceutical Co., Ltd. Ratios
JP:4534's free cash flow for Q1 2026 was ¥0.00. For the 2026 fiscal year, JP:4534's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.29 | 4.81 | 4.47 | 4.31 | 4.07 |
| Quick Ratio | 2.99 | 3.47 | 3.31 | 3.41 | 3.29 |
| Cash Ratio | 1.01 | 1.81 | 1.28 | 1.72 | 1.62 |
| Solvency Ratio | 0.26 | 0.26 | 0.24 | 0.29 | 0.38 |
| Operating Cash Flow Ratio | -0.27 | 0.38 | -0.29 | 0.27 | 0.25 |
| Short-Term Operating Cash Flow Coverage | -253.45 | 359.77 | -287.69 | 608.08 | 0.00 |
| Net Current Asset Value | ¥ 76.63B | ¥ 86.80B | ¥ 85.83B | ¥ 85.32B | ¥ 86.95B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.30 | 1.25 | 1.24 | 1.25 | 1.27 |
| Debt Service Coverage Ratio | 97.62 | 300.00 | 262.75 | 776.67 | 0.00 |
| Interest Coverage Ratio | 140.94 | 2709.00 | 2901.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 284.12 | 9.73 | 10.34 | 5.11 | 0.00 |
| Net Debt to EBITDA | -1.38 | -4.05 | -3.67 | -4.00 | -2.80 |
| Profitability Margins | |||||
| Gross Profit Margin | 48.11% | 51.15% | 50.61% | 53.37% | 54.05% |
| EBIT Margin | 8.68% | 7.73% | 5.99% | 8.76% | 13.24% |
| EBITDA Margin | 11.22% | 10.52% | 8.72% | 11.35% | 15.68% |
| Operating Profit Margin | 8.68% | 7.73% | 5.64% | 8.24% | 13.06% |
| Pretax Profit Margin | 9.55% | 7.66% | 5.99% | 8.76% | 13.24% |
| Net Profit Margin | 6.76% | 5.41% | 4.42% | 6.44% | 9.59% |
| Continuous Operations Profit Margin | 6.76% | 5.41% | 4.42% | 6.44% | 9.59% |
| Net Income Per EBT | 70.75% | 70.60% | 73.81% | 73.52% | 72.44% |
| EBT Per EBIT | 110.08% | 99.08% | 106.17% | 106.31% | 101.38% |
| Return on Assets (ROA) | 4.33% | 3.48% | 2.86% | 4.19% | 6.48% |
| Return on Equity (ROE) | 5.63% | 4.35% | 3.55% | 5.24% | 8.22% |
| Return on Capital Employed (ROCE) | 6.55% | 5.86% | 4.37% | 6.47% | 10.80% |
| Return on Invested Capital (ROIC) | 4.63% | 4.14% | 3.23% | 4.75% | 7.82% |
| Return on Tangible Assets | 4.35% | 3.50% | 2.88% | 4.21% | 6.51% |
| Earnings Yield | 6.44% | 5.04% | 3.96% | 5.36% | 7.43% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.21 | 3.33 | 2.95 | 3.71 | 3.48 |
| Payables Turnover | 5.63 | 5.93 | 4.17 | 5.32 | 4.75 |
| Inventory Turnover | 1.68 | 1.54 | 1.68 | 1.97 | 2.19 |
| Fixed Asset Turnover | 7.17 | 6.60 | 6.48 | 6.86 | 7.58 |
| Asset Turnover | 0.64 | 0.64 | 0.65 | 0.65 | 0.68 |
| Working Capital Turnover Ratio | 1.26 | 1.13 | 1.14 | 1.14 | 1.21 |
| Cash Conversion Cycle | 266.27 | 284.78 | 253.58 | 214.71 | 194.85 |
| Days of Sales Outstanding | 113.85 | 109.74 | 123.59 | 98.29 | 104.94 |
| Days of Inventory Outstanding | 217.24 | 236.57 | 217.48 | 185.01 | 166.74 |
| Days of Payables Outstanding | 64.81 | 61.53 | 87.50 | 68.59 | 76.83 |
| Operating Cycle | 331.08 | 346.31 | 341.08 | 283.30 | 271.68 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -207.33 | 263.86 | -208.57 | 196.37 | 195.76 |
| Free Cash Flow Per Share | -283.36 | 202.93 | -272.59 | 138.08 | 114.51 |
| Dividend Paid and CapEx Coverage Ratio | -1.33 | 1.87 | -1.44 | 1.32 | 1.14 |
| Capital Expenditure Coverage Ratio | -2.73 | 4.33 | -3.26 | 3.37 | 2.41 |
| Operating Cash Flow Coverage Ratio | -0.73 | 27.35 | -20.27 | 38.41 | 0.00 |
| Operating Cash Flow to Sales Ratio | -0.06 | 0.09 | -0.07 | 0.07 | 0.07 |
| Free Cash Flow Yield | -8.19% | 6.38% | -8.52% | 4.13% | 3.07% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 15.52 | 19.83 | 25.24 | 18.67 | 13.46 |
| Price-to-Sales (P/S) Ratio | 1.05 | 1.07 | 1.12 | 1.20 | 1.29 |
| Price-to-Book (P/B) Ratio | 0.87 | 0.86 | 0.90 | 0.98 | 1.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -12.21 | 15.67 | -11.74 | 24.19 | 32.62 |
| Price-to-Operating Cash Flow Ratio | -16.69 | 12.05 | -15.34 | 17.01 | 19.08 |
| Price-to-Earnings Growth (PEG) Ratio | 0.40 | 0.75 | -0.87 | -0.53 | 0.54 |
| Enterprise Value Multiple | 7.97 | 6.14 | 9.12 | 6.60 | 5.43 |
| Enterprise Value | 104.59B | 67.92B | 81.84B | 77.29B | 93.90B |
| EV to EBITDA | 7.97 | 6.14 | 9.12 | 6.60 | 5.43 |
| EV to Sales | 0.89 | 0.65 | 0.80 | 0.75 | 0.85 |
| EV to Free Cash Flow | -10.41 | 9.44 | -8.37 | 15.06 | 21.52 |
| EV to Operating Cash Flow | -14.23 | 7.26 | -10.94 | 10.59 | 12.59 |
| Tangible Book Value Per Share | 3926.85 | 3660.71 | 3548.09 | 3390.10 | 3357.57 |
| Shareholders’ Equity Per Share | 3958.42 | 3686.61 | 3568.22 | 3411.54 | 3376.28 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.29 | 0.29 | 0.26 | 0.26 | 0.28 |
| Revenue Per Share | 3299.04 | 2966.32 | 2868.83 | 2778.82 | 2891.69 |
| Net Income Per Share | 222.93 | 160.36 | 126.79 | 178.93 | 277.39 |
| Tax Burden | 0.71 | 0.71 | 0.74 | 0.74 | 0.72 |
| Interest Burden | 1.10 | 0.99 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.11 | 0.12 | 0.13 | 0.11 |
| SG&A to Revenue | 0.39 | 0.32 | 0.45 | 0.45 | 0.26 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.93 | 1.65 | -1.65 | 0.81 | 0.51 |
Currency in JPY
